About EyeBio
EyeBio is a company based in London (United Kingdom) founded in 2021 by Anthony Adamis was acquired by Merck Sharp & Dohme in May 2024. EyeBio has raised $130 million across 2 funding rounds from investors including Merck Sharp & Dohme, Bain Capital Life Sciences and Omega Funds. EyeBio offers products and services including Medicines and Vaccines. EyeBio operates in a competitive market with competitors including EyePoint Pharmaceuticals, Rezolute, Molecular Partners, Aviceda Therapeutics and IVERIC bio, among others.
- Headquarter London, United Kingdom
- Founders Anthony Adamis
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eyebiotech Limited
- Date of Incorporation 09 Jul, 2021
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
$20.88 K (USD)0as on Dec 31, 2022
-
EBITDA
$25.52 K (USD)0as on Dec 31, 2022
-
Total Equity Funding
$130 M (USD)
in 2 rounds
-
Latest Funding Round
$65 M (USD), Series A
Nov 14, 2023
-
Investors
Merck Sharp & Dohme
& 7 more
-
Employee Count
Not available
-
Acquired by
Merck Sharp & Dohme
(May 30, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EyeBio
EyeBio offers a comprehensive portfolio of products and services, including Medicines and Vaccines.
Treatments for diseases like diabetes and oncology
Preventive solutions for infectious diseases
People of EyeBio
Unlock access to complete
Unlock access to complete
Funding Insights of EyeBio
EyeBio has successfully raised a total of $130M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $65 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EyeBio
EyeBio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck Sharp & Dohme, Bain Capital Life Sciences and Omega Funds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked | |
|
Venture capital firm
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for EyeBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EyeBio
Investment portfolio details for EyeBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EyeBio
Detailed financials for EyeBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eyebio Comparisons
Peer comparison for EyeBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EyeBio
EyeBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as EyePoint Pharmaceuticals, Rezolute, Molecular Partners, Aviceda Therapeutics and IVERIC bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecule therapeutics for ophthalmic disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for diseases are developed using DARPin technology.
|
|
| Locked | Locked | Locked |
Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas.
|
|
| Locked | Locked | Locked |
Gene therapy solutions for retinal diseases are developed.
|
Detailed competitors of EyeBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eyebio
Complete news archive for EyeBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EyeBio
EyeBio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
EyeBio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
David Guyer is the current CEO of EyeBio.
EyeBio is a funded company, having raised a total of $130M across 2 funding rounds to date.
EyeBio was founded in 2021 and is headquartered in London, United Kingdom. Operations center on the biotechnology sector, where therapies for sight-threatening eye diseases are developed. Focus is placed on next-generation treatments to improve vision, including an anti-vascular endothelial growth factor drug targeted at age-related macular degeneration. Research and development activities are conducted to address unmet needs in ophthalmology.
EyeBio's top competitors include EyePoint Pharmaceuticals, Rezolute and Molecular Partners.
EyeBio offers Medicines and Vaccines.
EyeBio has 8 investors. Key investors include Merck Sharp & Dohme, Bain Capital Life Sciences, Omega Funds, Vertex Ventures HC, and SV Health Investors.